Bulletin
Investor Alert

New York Markets After Hours

Market Pulse Archives

May 4, 2021, 7:23 a.m. EDT

Lilly to donate experimental COVID-19 treatment Olumiant to India

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eli Lilly & Co. (LLY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY +0.66% gained 0.1% in premarket trading on Tuesday after the company said it will donate 400,000 doses of Olumiant, its rheumatoid arthritis drug that is being tested as a COVID-19 treatment for the severely ill in the U.S., to the Indian government. Lilly also said it will provide royalty-free licensing agreements to drug makers there to begin manufacturing the drug. Indian regulators on Monday authorized Olumiant as a treatment for severely ill COVID-19 patients as India's COVID-19 crisis continues to worsen. Lilly's stock is up 10.1% for the year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.04% has gained 11.6%.

/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 222.21
+1.45 +0.66%
Volume: 1.87M
June 17, 2021 4:04p
P/E Ratio
33.26
Dividend Yield
1.53%
Market Cap
$211.71 billion
Rev. per Employee
$701,137
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,221.86
-1.84 -0.04%
Volume: 2.57B
June 17, 2021 4:20p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.